Is no one safe from the FTC? Has Pfizer bottomed out? And is biotech finally back?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we delve into the fallout over the FTC’s move to block what looked like a humdrum biotech deal between Sanofi and Maze Therapeutics, a surprising twist that leaves an unanswered question. We also discuss the latest news in the life sciences, including Pfizer’s downbeat future, Vertex Pharmaceuticals’ next big thing, and a newly minted biotech VC with a very famous name.

More from STAT:

Become a subscriber: https://www.statnews.com/statplus/
Watch Full Episodes:    / @statnews  
Newsletters: https://www.statnews.com/signup/
STAT events: https://www.statnews.com/statevents/
Facebook:   / statnews  
Twitter:   / statnews  
Instagram:   / statnews  
Flipboard: rb.gy/3xnsxr
STAT Reports: https://rb.gy/rexfwj
STAT eBooks: https://rb.gy/eme3h5

ABOUT STAT:
Founded in 2015, STAT is a global digital media brand that focuses on delivering fast, deep, and toughminded journalism about the life sciences industries to over six million monthly site visitors and an additional 20 million readers on the Apple News app. STAT takes you inside academic labs, biotech boardrooms, and political backrooms, casting a critical eye on scientific discoveries, scrutinizing corporate strategies, and chronicling the roiling battles for talent, money, and market share. With an awardwinning newsroom, STAT provides indispensable insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving massive changes in the life sciences industry — and a revolution in human health.